⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890857 | 0.93 | — | — | |
| SCHEMBL24875353 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL29242483 | 0.82 | — | — | |
| SCHEMBL24736866 | 0.79 | OPRL1 (0.36) | — | |
| SCHEMBL26989054 | 0.76 | IDH1 (0.32) | — | |
| SCHEMBL28546508 | 0.72 | — | — | |
| SCHEMBL15545380 | 0.72 | PTPN11 (0.30) | — | |
| SCHEMBL25691976 | 0.72 | — | — | |
| SCHEMBL1583851 | 0.72 | OPRL1 (0.40) | — | |
| SCHEMBL18925572 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551571-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12098145-B2 | Oxazole TRPML1 agonists and uses thereof | LIBRA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024011155-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2022135567-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |